Federal Register / Vol. 65, No. 124 / Tuesday, June 27, 2000 / Notices 39623

POLICIES AND PRACTICES FOR STORING,

RETRIEVING, ACCESSING, RETAINING, AND

DISPOSING OF RECORDS IN THE SYSTEM:

STORAGE:

Information may be collected on

paper or electronically and may be

stored as paper forms or on computers.

RETRIEVABILITY:

The records are retrieved by name and

may also be cross-referenced to Social

Security Number.

SAFEGUARDS:

—Authorized Users: Only HHS

personnel working on this project and

personnel employed by HHS contractors

to work on this project are authorized

users as designated by the system

manager. —Physical Safeguards: Records are

stored in lockable metal file cabinets or

security rooms. —Procedural safeguards: Contractors

who maintain records in this system are

instructed to make no further disclosure

of the records, except as authorized by

the system manager and permitted by

the Privacy Act. Privacy Act

requirements are specifically included

in contracts.

—Technical Safeguards: Electronic

records are protected by use of

passwords. —Implementation Guidelines: HHS

Chapter 45–13 of the General

Administration Manual, Safeguarding

Records Contained in Systems of

Records and the HHS Automated

Information Systems Security Program

Handbook, Information Resources

Management Manual.

RETENTION AND DISPOSAL:

Disposition of records is according to

the National Archives and Records

Administration (NARA) guidelines.

SYSTEM MANAGER(S) AND ADDRESS:

The records of individuals applying

for and receiving child care subsidies

are managed by System Managers at the

various HHS sites listed in Appendix A.

NOTIFICATION PROCEDURE:

Individuals may submit a request

with a notarized signature on whether

the system contains records about them

to the local System Manager.

RECORD ACCESS PROCEDURES:

Request from individuals for access to

their records should be addressed to the

local System Manager. Requesters

should also reasonably specify the

record contents being sought.

Individuals may also request an

accounting of disclosures of their

records, if any.

CONTESTING RECORD PROCEDURES:

Contact the official at the address

specified under Notification Procedures

above and reasonably identify the

record, specify the information being

contested, and state the corrective

action sought, with supporting

information to show how the record is

inaccurate, incomplete, untimely, or

irrelevant.

RECORD SOURCE CATEGORIES:

Information is provided by HHS

employees who apply for child care

subsidies. Furnishing of the information

is voluntary.

SYSTEMS EXEMPTED FROM CERTAIN PROVISIONS

OF THE ACT:

None.

Appendix A

1. For employees of the Office of the

Secretary and the Administration on

Aging, nationwide, contact: Child Care

Program coordinator, PSC Work/Life

Center, Room 1250, 330 C Street, SW,

Washington, DC 20201. 2. For employees of the Substance

Abuse and Mental Health Services

Administration, contact: Director,

Division of Human Resources

Management, Office of Program

Services, Substance Abuse and Mental

health Services Administration, 5600

Fishers Lane, Rockville, Maryland

20857.

[FR Doc. 00–16230 Filed 6–26–00; 8:45 am]

BILLING CODE 4150–04–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Anti-Infective Drugs Advisory

Committee; Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public. Name of Committee: Anti-Infective

Drugs Advisory Committee. General Function of the Committee:

To provide advice and

recommendations to the agency on

FDA’s regulatory issues. Date and Time: The meeting will be

held on July 28, 2000, 8:30 a.m. to 5:30

p.m. Location: Parklawn Bldg., conference

rooms G and H, 5600 Fishers Lane, and

CDER Advisory Committee conference

room 1066, 5630 Fishers Lane,

Rockville, MD.

Contact Person: Thomas H. Perez,

Center for Drug Evaluation and Research

(HFD–21), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–6758, email: PerezT@cder.fda.gov, or FDA

Advisory Committee Information Line,

1–800–741–8138 (301–443–0572 in the

Washington, DC area), code 12530.

Please call the Information Line for upto-date information on this meeting.

Agenda: The committee will discuss

supplemental new drug applications

(NDA’s) 19–537/S038, 19–847/S024,

19–857/S027, 19–858/S021, 20–780/

S008 for Cipro (ciprofloxacin), Bayer

Corp. Pharmaceutical Division, for postexposure prophylaxis of clinical disease

from inhaled Bacillus anthracis.

Registration: Persons interested in

attending the meeting are required to

register by July 14, 2000. You may

register by submitting your name,

affiliation, telephone and fax number,

and e-mail address to Thomas Perez,

FAX 301–827–6801, or e-mail:

Perezt@cder.fda.gov. Registration

confirmation will be sent by e-mail or

facsimile on July 21, 2000.

Procedure: Interested persons may

present data, information, or views,

orally or in writing, on issues pending

before the committee. Written

submissions may be made to the contact

person by July 19, 2000. Oral

presentations from the public will be

scheduled between approximately 1:30

p.m. and 2:30 p.m. Time allotted for

each presentation may be limited. Those

desiring to make formal oral

presentations should notify the contact

person before July 19, 2000, and submit

a brief statement of the general nature of

the evidence or arguments they wish to

present, the names and addresses of

proposed participants, and an

indication of the approximate time

requested to make their presentation.

Notice of this meeting is given under

the Federal Advisory Committee Act (5

U.S.C. app. 2).

Dated: June 19, 2000.

Linda A. Suydam,

Senior Associate Commissioner.

[FR Doc. 00–16123 Filed 6–26–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Antiviral Drugs Advisory Committee;

Notice of Meeting

AGENCY: Food and Drug Administration,

HHS.